To Assess Liraglutide's Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System.
To Assess Liraglutide's Therapeutic Effect in Patients with Type 2 Diabetes Mellitus Using Flash Glucose Monitoring System.
复制标题
使用快速血糖监测系统评估利拉鲁肽对 2 型糖尿病患者的治疗效果
DOI：
10.2147/dmso.s331833
复制
发表时间：
2021
期刊：
影响因子：
--
通讯作者：
Liu Y
中科院分区：
文献类型：
--
作者：
Yin J;Han M;Li L;Li Y;Liu Z;Yang J;Liu Y
目的：利拉鲁肽是一种胰高血糖素样肽-1受体激动剂，具有显著的抗高血糖活性，但不增加低血糖的发生率。此外，它还可以改善β细胞功能和胰岛素抵抗。瞬时血糖监测系统（FGMS）是一种记录连续和详细间质血糖水平的新方法，可以进一步反映血糖水平。本研究旨在探讨利拉鲁肽对糖尿病患者血糖管理（血糖变异性、高血糖和低血糖发生率）、β细胞功能和胰岛素抵抗的治疗效果。患者和方法：本研究招募33例2型糖尿病患者。在二甲双胍单药治疗的基础上，这些患者接受利拉鲁肽附加治疗3个月。FGMS用于记录附加治疗前后的血糖水平。根据FGMS数据评估血糖变异性参数、特定时间段的血糖水平和低血糖发生率，并比较利拉鲁肽附加治疗前后的差异。进一步评估β细胞功能和胰岛素抵抗，并比较利拉鲁肽加药前后的差异。结果：根据FGMS监测数据，利拉鲁肽附加治疗显著改善了一般、日间和日常血糖变异性和血糖靶率。此外，特别分析了不同时间段的血糖水平，结果表明，在附加治疗后，夜间、禁食和餐后的血糖水平显著降低。根据预先设定的临界值（3.9 mmol/L和3.0 mmol/L），加药前后全天、白天和夜间的低血糖发生率具有可比性。对其他评估参数的分析显示，在附加治疗前后，糖化血红蛋白A1c和空腹血糖水平以及β细胞功能和胰岛素抵抗参数存在显著差异。结论：利拉鲁肽治疗2型糖尿病可有效降低血糖变异性，改善高血糖，且不增加低血糖的发生率。利拉鲁肽能显著改善β细胞功能，改善胰岛素抵抗。
Purpose:Liraglutide, a type of glucagon-like peptide-1 receptor agonist, has significant anti-hyperglycaemic activity without increasing the incidence of hypoglycaemia. In addition, it can improve β-cell function and insulin resistance. The flash glucose monitoring system (FGMS) is a novel method to document consecutive and detailed interstitial glucose levels, further reflecting blood glucose levels. This study aimed to investigate the therapeutic effect of liraglutide on blood glucose management (glucose variability, hyperglycaemia, and the incidence of hypoglycaemia), β-cell function, and insulin resistance in patients with diabetes.Patients and methods:Thirty-three patients with type 2 diabetes mellitus were recruited in this study. On the basis of metformin monotherapy, these patients received liraglutide add-on treatment for 3 months. The FGMS was used to document glucose levels before and after add-on treatment. Parameters of glucose variability, blood glucose levels at specific time periods, and the incidence of hypoglycaemia were assessed according to FGMS data and compared before and after liraglutide add-on treatment. Further, β-cell function and insulin resistance were assessed and compared before and after liraglutide add-on treatment.Results:According to FGMS monitoring data, liraglutide add-on treatment significantly improved general, within-day, and day-to-day glucose variability and the glucose-target-rate. Further, the specifically analysed blood glucose levels at different time periods showed that blood glucose levels significantly decreased at nocturnal, fasting, and postprandial periods after add-on treatment. The incidence of hypoglycaemia was comparable during the whole day, daytime, and night-time according to the prespecified cutoffs (3.9 mmol/L and 3.0 mmol/L) before and after add-on treatment. Analysis of other assessed parameters revealed significant differences in glycosylated hemoglobin A1c and fasting blood glucose levels as well as parameters of β-cell function and insulin resistance before and after add-on treatment.Conclusion:In type 2 diabetes mellitus, liraglutide treatment can effectively decrease glucose variability and ameliorate hyperglycaemia without increasing the incidence of hypoglycaemia. In addition, liraglutide can significantly improve the β-cell function and insulin resistance.